Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner(Universitätsklinikum Würzburg), Bernard Zinman(Mount Sinai Hospital)
Cited by 3,602
Related Papers
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
|New England Journal of Medicine|2015|11.9k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k
Impaired Fasting Glucose and Impaired Glucose Tolerance
|Diabetes Care|2007|1.4k
Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease
|New England Journal of Medicine|2013|990